KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Hematology / 2013 / Cilt: 30 - Sayı: 3

The impact of eltrombopag administration on the clinical course of severe refractory fatal acquired aplastic anemia

Ayşe IŞIK
Eylem ELİAÇIK
C. İbrahim HAZNEDAROĞLU
Salih AKSU
Nilgün SAYINALP
Yahya BÜYÜKAŞIK
Hakan GÖKER
Osman ÖZCEBE
Sayfa
328–330
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

IŞIK, A., ELİAÇIK, E., HAZNEDAROĞLU, C. İ., AKSU, S., SAYINALP, N., BÜYÜKAŞIK, Y., GÖKER, H., ÖZCEBE, O. (2013). The impact of eltrombopag administration on the clinical course of severe refractory fatal acquired aplastic anemia. Turkish Journal of Hematology, Cilt: 30 - Sayı: 3, 328–330. https://ajindex.com/articles/412629

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (6)

  1. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012;120:1185-1196
  2. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013;121:537-545
  3. Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med 2012;367:11-19
  4. Sitnicka E, Lin N, Priestley GV, Fox N, Broudy VC, Wolf NS, Kaushansky K. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood 1996;87:4998-5005
  5. Haznedaroglu IC, Goker H, Turgut M, Buyukasik Y, Benekli M. Thrombopoietin as a drug: biologic expectations, clinical realities, and future directions. Clin Appl Thromb Hemost 2002;8:193-212
  6. Nagasawa T, Hasegawa Y, Shimizu S, Kawashima Y, Nishimura S, Suzukawa K, Mukai H, Hori M, Komeno T, Kojima H, Ninomiya H, Tahara T, Abe T. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br J Haematol 1998;101:242-244.